PERFORATIONS AND FISTULAS, and HEMORRHAGE
See full prescribing information for complete boxed warning.
Litt's app available free to subscribers - download for IOS and Android from the App Store or Google Play.
- TRADE NAMES: Carbometyx (Exelixis); Cometriq (Exelixis)
- INDICATIONS: Metastatic medullary thyroid cancer (Cometriq); advanced renal cell carcinoma (Cabometyx)
- CLASS: Angiogenesis inhibitor / antiangiogenic agent, MET (mesenchymal-epithelial transition) inhibitor / MET tyrosine kinase inhibitor, RET (Rearranged during Transfection) kinase inhibitor, Tyrosine kinase inhibitor, Vascular endothelial growth factor (VEGF) inhibitor / antagonist
- HALF-LIFE: 55 hours (Cometriq); 99 hours (Cabometyx)
- FDA APPROVAL DATE: 11/30/2012 (Cometriq); 04/25/2016 (Cabometyx)
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Atazanavir, Boceprevir, Carbamazepine, Clarithromycin, Conivaptan, Grapefruit Juice, Indinavir, Itraconazole, Ketoconazole, Lopinavir, Nefazodone, Nelfinavir, Phenobarbital, Phenytoin, Posaconazole, Rifabutin, Rifampin, Rifapentine, Ritonavir, Saquinavir, St John's Wort, Telithromycin, Voriconazole
Please login to view the rest of this drug profile.
Page last updated 09/30/2025
